Press releases

Stockholm – February 21, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2023 year-end report, at 08:00 (CET) on February 27, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET

Stockholm, February 15, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years

Stockholm – December 15, 2023 – Oncopeptides today announces that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains

Stockholm – November 17, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, has been published in the European Journal of Haematology, an international journal for communication of research in hematology. The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease

Stockholm – November 13, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12

Stockholm – November 13, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult to treat cancers, today announces that Henrik Bergentoft today takes office as the company´s new Chief Financial Officer

Stockholm – November 8, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2023

STOCKHOLM – November 1, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter 2023 at 08:00 CET on November 8. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 8 at 09:00 CET

Stockholm – October 20, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers today announces that the composition of the Nomination Committee has been established

STOCKHOLM — September 29, 2023 — Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed due to exercise of warrants under the company´s incentive program. Through the exercise of the warrants the number of outstanding shares and votes has increased by 70,967 from 94,529,110 to 94,600,077. The share capital has increased with SEK 7,886 from SEK 10,503,235 to SEK 10,511,120